Nucleosome accumulation and reduction of C-reactive protein are associated with the generation of anti-nuclear antibodies in patients with rheumatoid arthritis treated with adalimumab, but not with etanercept

Annals of the Rheumatic Diseases

Volumn 68, Issue 9, 2009, Pages 1514-1516

  Priori, R ^a   Alessandri, C ^a   Magrini, L ^a   Cassara E A M ^a   Ceccarelli, F ^a   Modesti, M ^a   Croia, C ^a   Bombardieri, M ^b   Valesini, G ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTINUCLEAR ANTIBODY; AUTOANTIBODY; C REACTIVE PROTEIN; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; DISEASE MODIFYING ANTIRHEUMATIC DRUG; DOUBLE STRANDED DNA ANTIBODY; ETANERCEPT; NUCLEOSOME ANTIBODY; RHEUMATOID FACTOR; STEROID;

ANTIBODY TITER; HUMAN; LETTER; MAJOR CLINICAL STUDY; NUCLEOSOME; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; TREATMENT DURATION; TREATMENT OUTCOME;

ANTIBODIES, ANTINUCLEAR; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; C-REACTIVE PROTEIN; HUMANS; IMMUNOGLOBULIN G; NUCLEOSOMES; RECEPTORS, TUMOR NECROSIS FACTOR;

EID: 69949152982     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2008.103291     Document Type: Letter

References (10)

1. Scott DL, Kingsley GH. Tumor necrosis factor inhibitors for rheumatoid arthritis. N Engl J Med 2006;355:704-712 (Pubitemid 44244541)
2. Bobbio-Pallavicini F, Alpini C, Caporali R, Avalle S, Bugatti S, Montecucco C. Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment. Arthritis Res Ther 2004;6:R264-72.
3. Eriksson C, Engstrand S, Sundqvist KG, Rantapää-Dahlqvist S. Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF-α. Ann Rheum Dis 2005;64:403-407 (Pubitemid 40283050)
4. D'Auria F, Rovere-Querini P, Giazzon M, Ajello P, Baldissera E, Manfredi AA, et al. Accumulation of plasma nucleosomes upon treatment with anti-tumour necrosis factor-α antibodies. J Intern Med 2004;255:409-418 (Pubitemid 38315283)
5. Cantaert T, De Rijcke L, Mavragani CP, Wijbrandts CA, Niewold TB, Niers T, et al. Exposure to nuclear antigens contributes to the induction of humoral autoimmunity during TNFα blockade. Ann Rheum Dis 2009;68:1022-1029
6. Lorenz HM, Herrmann M, Winkler T, Gaipl U, Kalden JR. Role of apoptosis in autoimmunity. Apoptosis 2000;5:443-449
7. Lauber K, Blumenthal SG, Waibel M, Wesselborg S. Clearance of apoptotic cells: getting rid of the corpses. Mol Cell 2004;14:277-287 (Pubitemid 38607340)
8. Catrina AI, Trollmo C, af Klint E, Engstrom M, Lampa J, Hermansson Y, et al. Evidence that anti-tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: extended report. Arthritis Rheum 2005;52:61-72.
9. Shen C, Maerten P, Geboes K, Van Assche G, Rutgeerts P, Ceuppens JL. Infliximab induces apoptosis of monocytes and T lymphocytes in a human-mouse chimeric model. Clin Immunol 2005;115:250-259 (Pubitemid 40716048)
10. Kravitz MS, Shoenfeld Y. Autoimmunity to protective molecules: is it the perpetuum mobile (vicious cycle) of autoimmune rheumatic diseases? Nat Clin Pract Rheumatol 2006;2:481-490